


New development of the dermatology area

REIG JOFRE LAUNCHES **COMPLIDERMOL 5 α PLUS**, A DIETARY SUPPLEMENT FOR THE TREATMENT OF FEMALE ANDROGENETIC ALOPECIA



- Complidermol 5 α PLUS is the first dietary supplement for female androgenetic alopecia which, thanks to its novel formulation developed by the R&D team at Reig Jofre, tackles not only the known hormonal factor, but also the oxidative and inflammatory factors, new pathophysiological factors identified as causes of this condition.
- Female androgenetic alopecia currently affects around 40% of women over 50, with significant impact on their psychological wellbeing and quality of life and accounting for 3% to 8% of first appointments with dermatologists.
- Complidermol 5 α PLUS results from combining two key strategic areas for Reig Jofre – dermatology and dietary supplements – where the company is widening its approach to healthcare through prevention.
- Reig Jofre is at the forefront of the Spanish market in the treatment for this condition, where it has over ten years' experience in development and marketing.

Barcelona, February 15, 2017. Pharmaceutical company Reig Jofre launches **Complidermol 5 α PLUS**, a dietary supplement offering a more comprehensive clinical approach to female androgenetic alopecia (FAA), which currently affects around 40% of women over 50.

Reig Jofre has over ten years' experience in the treatment of female androgenetic alopecia and is market leader in Spain. Complidermol 5 α PLUS results from combining two key strategic areas for Reig Jofre – dermatology and dietary supplements – where the company is widening its approach to healthcare through prevention.



Following an in-depth review of the scientific literature on this condition, experts have concluded that, in addition to the genetic and hormonal factors known and treated to date in FPB, there are also other factors which can be considered responsible for this condition, such as oxidative stress and micro-inflammation in the affected area.

Complidermol 5a PLUS has an increased effect on the known hormonal factor and in addition treats these newly-identified pathophysiological factors, which play a part in the shrinkage of hair follicles characteristic of this condition.

Complidermol 5a PLUS has been developed to slow down the progression of FAA, revitalise the hair follicle and lengthen the anagen phase of hair growth. The aim is to improve hair quality and the quality of life of women suffering from this condition.

Beneficial for all women suffering from this condition

FAA currently affects around 40% of women over 50 and accounts for 3% to 8% of first appointments with dermatologists. It is an issue which significantly affects the psychological wellbeing and quality of life of women affected – statistics reveal that it is an area of concern for 52% of them, whereas only 28% of men consider hair loss to be a problem.

The peak reached in this age group due to lower oestrogen activity after menopause is the main reason for hormonal factors having been the primary therapeutic target up until now, along with genetic factors. However, a review of new scientific evidence has led experts to focus on these new factors, which Complidermol 5a PLUS is the first to address.

It is a new milestone for Reig Jofre and its R&D department, through which the company places all its scientific expertise at the service of patients in order to offer innovative dermatological treatments, a therapeutic area in which, along with gynaecology, Reig Jofre specialises.

Reig Jofre's dermatology range accounted for 13% of the company's total sales in 2015 (last year reported), reaching 20.4 million euros, a 22% increase over the previous year.

This new formulation is now being launched in Spain, but the company does not rule out launching it in other markets in the future.



Get timely updates of Reig Jofre news by registering in the company's **subscription centre** on the corporate website: **www.reigjofre.com**

About Reig Jofre

Founded in Barcelona in 1929, Reig Jofre is a multinational pharmaceutical company with activity structured around two major axes: the main one, own-product manufacture and marketing (RJF Pharma, 80% of total sales) and a complementary one, development and manufacture for third parties (RJF CDMO, 20% of total sales). In its main activity, the company focuses on developing specialised technological products (antibiotics and solutions for injection); specialised therapeutic products for the dermatology, gynaecology and respiratory fields; and dietary supplements and consumer healthcare. The company focuses its R+D activity on developing new indications and/or pharmaceutical forms using known active substances, generic medicines with a particular focus on beta-lactam antibiotics and solutions for injection, topical dermatological products, OTCs and dietary supplements, and in addition develops new innovative molecules in partnership with start-ups and research centres.

Reig Jofre has 900 employees, 4 development centres and 3 production centres in Europe, direct sales in 6 European countries and over 130 business partners in 58 countries across the world. The company closed 2015 with a turnover of 157 million euros.

Reig Jofre is listed on the Spanish Stock Exchange under the ticker RJF. Reig Jofre is listed on the Spanish Stock Exchange under the ticker RJF. Share capital: 63,214,220 shares.

For further information:

Investors and analysts

Gloria Folch
Tel. (+34) 93 480 67 10 – ext. 1241
gloria.folch@reigjofre.com

Media

Inma Santa-Pau
Tel. (+34) 93 480 67 10 – ext. 1242
inma.santapau@reigjofre.com